Therapeutic Potential of Epigallocatechin Gallate Nanodelivery Systems

Table 5

Other EGCG nanocarriers. Note. N/A denotes “not available” data.

Particle	Loading capacity (%)	Loading efficiency (%)	Size (nm)	Administration route	In vitro/in vivo results	Ref.
Selenium	N/A	N/A	29	N/A	Enhanced capacity to inhibit Aβ fibrillation and promote fibril disaggregation. Protection of PC-12 against Aβ-mediated toxicity.	[54]
Transfersomes	N/A	76.5	101.2	Topical	Increased ability to suppress lipid peroxidation, ROS generation, and MMPs expression.; Enhanced ex vivo skin permeation and deposition of EGCG across rat skin.	[55]
Peptide dendrimers (glycine, proline, lysine, and arginine)	N/A	N/A	N/A	Topical	Enhanced ex vivo skin permeation and deposition of EGCG across rat skin.	[56]
Gelatin	N/A	97.13	168.87	Ocular	Inhibition of HUVECs proliferation and migration.; Inhibition of vessel formation in a corneal neovascularization mouse model.	[57]
β-Lactoglobulin-chlorogenic acid	~7.3	~73	~110	N/A	Enhanced EGCG stability in physiological environments. Controlled release in simulated gastric and intestinal environments.	[58]